

13 February 2025

## Argent BioPharma Ltd.

(Argent BioPharma or the Company)

### Update on SINTEF Collaboration for Advanced Chronic Wound Management

#### Key Highlights:

- Argent BioPharma has made significant progress in optimising proprietary antimicrobial compounds for nano-encapsulation, enhancing drug efficacy and targeted delivery for chronic wounds and potentially oncologic wound care.
- Key milestones achieved for the establishment of standardised in vitro assays, selection of Synthetic Wound Fluid (SWF) as the optimal testing medium, and identification of promising active pharmaceutical ingredients (APIs) with pH-dependent antimicrobial activity, guiding future formulation strategies.
- Addressing Critical Unmet Needs in Wound Care & Oncology – The initiative targets diabetic foot ulcers, pressure sores, post-surgical infections, and potentially non-melanoma skin cancer (NMSC) excisions, tackling biofilm formation, antibiotic resistance, and chronic infections in a market projected to exceed \$15 billion globally by 2030<sup>1</sup>.

Argent BioPharma is a clinical-stage biopharma company focused on **neuroimmunology** and **nano-medicines** for **CNS disorders** and **immune-related conditions**. Utilising its **Neuro-Immune Modulatory (NIM) System**, through science-driven innovation, is pleased to provide an update on the ongoing collaboration with SINTEF.

Argent BioPharma has made significant progress in its collaboration to develop advanced antimicrobial therapies for chronic wound infections and potentially skin cancer-related wounds, leveraging nano-encapsulation technology to enhance drug efficacy and targeted delivery. In the first phase, standardised in vitro assays were established for microbial strains relevant to chronic wounds, with Synthetic Wound Fluid (SWF) identified as the optimal testing medium. Screening of multiple active pharmaceutical ingredients (APIs) revealed promising candidates, with findings indicating that antimicrobial efficacy varies with pH—critical for formulation development.

Moving forward, the project will refine API combinations for nano-encapsulation and conduct Minimum Inhibitory Concentration (MIC) studies to assess synergistic antimicrobial effects. This initiative addresses a critical need in chronic wound management, where persistent infections, biofilm formation, and antibiotic resistance pose significant treatment challenges. Additionally, the technology may have broader applications in oncologic wound care, particularly in managing non-melanoma skin cancer (NMSC) excisions, where infection control and enhanced healing are crucial.

Targeting conditions such as diabetic foot ulcers, pressure sores, post-surgical wounds, and potentially skin cancer-related lesions, Argent BioPharma's nanotechnology-driven approach aims to improve healing outcomes, reduce antibiotic dependence, and position itself at the forefront of the rapidly expanding advanced wound care and oncologic wound management markets, collectively projected to exceed \$15 billion globally by 2030<sup>1</sup>.

Since the inception of the collaboration<sup>2</sup>, significant progress has been made in the project's first phase, which aims to evaluate the antimicrobial properties of Argent's selected compounds and establish optimal combinations for nano-encapsulation.

<sup>1</sup> <https://www.grandviewresearch.com/industry-analysis/advanced-wound-care-market>

<sup>2</sup> Refer to Announcement dated 21 August 2024



Key milestones achieved include:

- **Establishment of In Vitro Assays:**
  - Standardised testing conditions achieved for microbial strains relevant to chronic wound infections.
  - Growth experiments conducted in multiple wound-fluid models, leading to the selection of Synthetic Wound Fluid (SWF) as the most suitable medium.
- **Screening of Antimicrobial Activity:**
  - A panel of active pharmaceutical ingredients (APIs) was tested for antimicrobial efficacy, with certain compounds emerging as the most promising candidates.
  - Initial findings indicate that the antimicrobial activity of key compounds varies based on pH levels, informing formulation strategies.

Looking ahead, the next phase of the collaboration will focus on:

- Refining the most promising API combinations for nano-encapsulation.
- Conducting minimum inhibitory concentration (MIC) assessments to evaluate the synergistic effects of lead compounds.

This collaboration continues to align with Argent BioPharma's vision of pioneering novel therapeutic solutions to address unmet medical needs in chronic wound care. The Company remains committed to progressing this innovative approach and will provide further updates as development milestones are achieved.

—Ends—

Authorised for release by the board of directors, for further information please contact:

**Argent BioPharma**  
Roby Zomer  
CEO & Managing Director  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma**  
Rowan Harland  
Company Secretary  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma Ltd**  
Suite 1, 295 Rokeby Road  
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 [info@argentbiopharma.com](mailto:info@argentbiopharma.com)





## About Argent BioPharma

Argent BioPharma Limited (ASX: RGT; OTCQB: RGTLF) is an innovative clinical-stage biopharmaceutical company specialising in neuroimmunology, developing advanced nano-medicines to address unmet medical needs in central nervous system (CNS) disorders and immune-related conditions. By leveraging cutting-edge technologies, including the Neuro-Immune Modulatory (NIM) System and its role in coordinating nervous and immune responses, Argent BioPharma's robust pipeline—featuring lead candidates like CannEpil®, CogniCann®, and CimetrA®—targets complex diseases where effective treatments are lacking. Through a commitment to science-driven innovation and patient-centered outcomes, Argent BioPharma is reshaping the future of care for chronic, inflammatory, and neurodegenerative diseases

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

## About SINTEFF

SINTEF is one of Europe's largest independent research institutes, founded in 1950, with expertise spanning technology, natural sciences, and social sciences. The institute drives innovation through research and development projects for both business and the public sector, tackling global challenges across various industries. SINTEF's research focuses on areas including **building and construction, climate and environment, digitalisation, health and medicine, renewable energy**, and **sustainable production**, among others. Recent initiatives include projects like **INTERPORT**, aiming to enhance port investments with sustainable technologies, **CO2Value**, focused on transforming CO<sub>2</sub> emissions into sustainable feed ingredients, and **SKARV**, which works to reduce bird collisions with wind turbines while maintaining energy production. SINTEF's commitment to solving critical societal and environmental issues through interdisciplinary research positions it at the forefront of innovation and sustainability.



**Argent BioPharma Ltd**  
Suite 1, 295 Rokeby Road  
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 [info@argentbiopharma.com](mailto:info@argentbiopharma.com)